Biocracked
**Approach:** Conceptual metaphor. **Palette:** D, bold color field.

A single AA-style battery stands upright on a saturated tomato-red matte backdrop. Its casing is cleanly cut away so the cells inside show as a real cross-section. A thin, steady bead of electric green gel or liquid sits at a constant level inside the cell. Beside it, a worn analog pressure gauge on a rubber tube, its needle pushed into the upper range, stands for hypertension. A white coiled stethoscope tubing curls loosely across the foreground.

Shot at a slightly low, eye-level three-quarter angle with a 50mm lens and shallow depth of field. Lighting is hard, crisp studio key light from the upper left. It casts sharp, warm-neutral shadows on the red surface and bright specular highlights on the metal.

The mood is skeptical and analytical: stable, not draining, with the real warning sign sitting next to it.
Longevity

Blood NAD Doesn't Fall With Age. It Tracks Heart Disease Instead

Dr. Synapse · · 4 min read

For years, the pitch for NAD+ boosters has rested on one simple claim: NAD declines with age, so you should replace what you are losing. A new paper in Nature Metabolism challenges the premise, at least when NAD is measured in human blood. In healthy adults, whole-blood NAD did not fall with age. What did predict lower levels was cardiovascular disease and hypertension.

What the Study Actually Found

The research, led by Romenskaja-Avgul, Stakelytė and Laurynėnas, analyzed 1,340 whole-blood NAD measurements from 1,068 adults. The aim was to settle a long-running dispute over whether blood NAD changes with ageing or with disease.

The results split into two findings.

  • In healthy individuals, NAD does not decline with age. Levels stayed stable in males and increased in females.
  • In chronic disease, NAD is lower. The reductions were linked specifically to cardiovascular disease and hypertension.

The authors summarize this as whole-blood NAD tracking cardiovascular disease rather than chronological age.

The idea that NAD falls steadily through adulthood is one of the most repeated claims in longevity circles. It is often traced to tissue and animal studies, along with smaller human datasets, and it underpins a large market for NAD precursors such as NR and NMN, plus IV NAD+ clinics.

This study does not show that tissue NAD never declines. It measures whole blood, a single compartment, and blood is not muscle, brain, liver or fat. But the dataset is large for this field, and it directly contradicts the assumption that a blood-based NAD reading drops simply because you have had more birthdays.

The practical implication is that age alone may be a poor reason to assume your blood NAD is low. If a person is healthy, the "you're losing NAD as you get older" argument may not apply to their circulating levels.

The Sex Difference Is Worth Noticing

The sex-specific pattern is one of the more intriguing details. Healthy males stayed stable, while healthy females showed an increase with age. A simple linear-decline model would not predict that. The abstract gives no mechanism, so any explanation, such as hormonal changes, differences in blood composition or shifts in red blood cell content, would be speculation. It does suggest that "NAD and age" is not one universal curve, and that studies pooling men and women together may blur important differences.

Cardiovascular Disease and Hypertension: The Real Signal

The strongest signal in the data is the link between lower whole-blood NAD and cardiovascular disease and hypertension. This fits a broader scientific interest in NAD metabolism and vascular health, since NAD is central to cellular energy handling and redox balance, and the cardiovascular system is metabolically demanding.

But the direction of the relationship matters, and this study cannot resolve it. Lower NAD might contribute to disease. Disease processes, inflammation, medications or lifestyle factors tied to illness might lower NAD. Or a third factor might drive both. The authors are explicit on this point.

The Critical Caveat: No Proof of Treatment

The authors state plainly that the research was not designed to investigate causality. Their data therefore do not provide direct evidence that NAD supplementation may serve as a treatment for cardiovascular disease or hypertension.

This is easy to overlook in a field that moves quickly from association to product. A low biomarker in sick people does not mean raising the biomarker will make them well. Many biomarkers that track disease turn out to be consequences, not levers. Only interventional trials can show whether restoring NAD changes outcomes.

Practical Takeaways for Biohackers

For people who track their own biomarkers, the study suggests a few ways to think about NAD data.

  1. Don't assume age means low NAD. If you are healthy, a decline in blood NAD is not a given just because you are older.
  2. Treat a low reading as a possible health flag, not an age verdict. A low whole-blood NAD might be worth discussing with a clinician alongside blood pressure, lipids and other cardiovascular markers.
  3. Context matters more than a single number. Sex, health status and measurement method all affect interpretation. This study used whole blood, and results may not translate to other sample types or to tissue levels.
  4. Be skeptical of supplement logic built on age alone. "I'm 50, so I need NAD precursors" is not supported by these blood data.
  5. Don't self-treat cardiovascular conditions with NAD products. The authors say the data do not support supplementation as a treatment for these conditions. Standard medical care for hypertension and heart disease remains the evidence-based route.
  6. Consider tracking over time. The study included repeat measurements in some participants, and personal trends may be more informative than a single snapshot.

Limits and Open Questions

Several questions remain open. Whole-blood NAD is dominated by red blood cells, so it may not reflect NAD in the tissues where age-related decline has been proposed. The abstract does not detail the measurement platform, medication effects or participant demographics, so readers should consult the full paper before drawing finer conclusions. And the central question of whether low NAD in cardiovascular disease is cause, consequence or bystander is untouched.

The Bottom Line

This study shifts the question from "does NAD fall with age?" to "what does a low blood NAD tell us about health?" The answer, in this dataset, is that it may say more about your cardiovascular status than your birth year. That makes whole-blood NAD a potentially interesting marker, but not yet a proven therapeutic target. For anyone weighing supplements, the honest message is that the age-decline argument is weaker than commonly claimed, and the disease-treatment argument still needs clinical trials.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 Calmed 'Old' Platelets in Aged Mice—Here's the Catch

BY NOVA CHEN ·

A new Aging Cell study reports that CoQ10 improved the function of aged megakaryocytes, the bone marrow cells that make platelets, in mice. Treated animals showed reduced platelet aggregation and activation, though platelet counts didn't change. The effect appeared to run partly through COPS3 and autophagy, the cell's recycling system. But this was mouse and cell-line research with no human data and no proof of clot prevention. Here is what it means, what it doesn't, and why people on blood thinners should talk to a doctor first.

Approach: Lab in action. Palette: B, warm.

Close, slightly high three-quarter angle on an isolated rat heart suspended in a Langendorff perfusion rig, the small dark-red heart held by its aorta on a glass cannula inside a warm-jacketed glass chamber. Clear perfusion fluid drips from the heart and beads on the glass. A gloved hand in the soft-focus foreground adjusts a stopcock. Amber, honey-colored light from a low side lamp rakes across the curved glass, producing copper highlights and warm brown shadows. Behind it, a blurred bench holds tubing and a small pressure transducer. A thin electric green (#00e676) indicator light glows on the instrument at the edge of the frame. Mood: quiet, focused, cautiously hopeful, with real laboratory texture and shallow depth of field. No text or labels.
longevity

Two Popular Supplements Shielded Old Rat Hearts. Here's the Catch

BY DR. SYNAPSE ·

A new rat study found that pairing NMN with melatonin helped aged hearts recover from a heart-attack-style injury better than either compound alone. Treated hearts showed improved coronary flow and pressure recovery, along with lower creatine kinase and inflammatory markers. But the work was done on isolated rat hearts, with melatonin delivered in the perfusion fluid and NMN given by injection. That means it says nothing yet about taking supplements as pills or about human benefit. Here is what the researchers did, what they found, and why it is only a first step.

Approach: conceptual metaphor. Palette: D, bold color field.

A tall glass of bright orange-gold liquid sits in the center of the frame, filled to the brim and overflowing down its sides, shot at a slight low angle. Beside it, a sealed, empty glass cylinder with a thin glass wall stays bone dry. A clear glass barrier stands between them, so the flow clearly never crosses. The backdrop is a saturated tomato-red seamless paper, with a glossy red surface reflecting both vessels. Hard, directional studio light from the upper left throws crisp, warm-neutral shadows and bright highlights along the glass rims and liquid droplets. One small electric green ring sits at the base of the empty cylinder as a subtle accent. Mood: tense, ironic, clean and editorial. Photorealistic, shallow depth of field, no text or labels.
supplements

Your CoQ10 Reaches Your Blood, But Not Your Mitochondria

BY NOVA CHEN ·

A new human trial put a hugely popular longevity supplement to the test with muscle biopsies, and the results are awkward for the marketing. In 40 healthy adults averaging 74 years, 400 mg/day of CoQ10 for 12 weeks raised blood levels but left muscle and mitochondrial CoQ10 unchanged. Mitochondrial function, VO2max, glucose control and body composition did not move either. The study is small, short and limited to robust older adults, and the senior author consults for Pharma Nord. Here is what it shows, what it cannot say, and who might still want to ask a doctor about CoQ10.

Approach: conceptual metaphor. Palette: D, bold color field.

A single cracked ceramic-white bone-shaped column, like a femur section, stands upright at the center of a saturated mustard-yellow seamless backdrop. A thin, clean hairline fracture runs through its middle. Beside it, a small golden-amber glass dropper bottle sits tipped, with one droplet suspended just above the bone and not touching it, which suggests extra vitamin D that makes no difference. The camera is at a low three-quarter angle with a shallow depth of field. Hard, directional studio light from the upper left casts a crisp, long shadow across the yellow floor. The porous bone texture is visible in fine detail. A tiny electric green (#00e676) droplet reflection glints on the glass. The mood is skeptical, cool-headed and editorial.
longevity

High-Dose Vitamin D for Bones? A 5-Year Trial Says No

BY DR. SYNAPSE ·

Taking extra vitamin D to keep your bones strong? A five-year randomized trial in 2,495 older Finns found that neither 1,600 nor 3,200 IU/day reduced fractures compared with placebo. Oddly, the 1,600 IU group had more fractures (HR 1.52), though the higher dose showed no such effect, which suggests chance may be at play. Participants already had sufficient vitamin D at baseline, so the results may not apply to people who are deficient. Here is what the study found, what its limits are, and what to do before buying another bottle.

This page is available in